Rhee TG

Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.

Rhee TG

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.

Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.

A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression.

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

Structural Neurotoxic and Neuroprotective Effects of Ketamine and Esketamine in Preclinical and Human Studies: A Systematic Review

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.

Concurrent SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment.

Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?

Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.

The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review.

Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.

Questionable Data and Design in Esketamine Study.

Ketamine and Esketamine: Is There a Meaningful Clinical Difference?

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023.

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.

Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.